Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

BACKGROUND: Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non‐small‐cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second‐line treatment after chemoimmunotherapy is cru...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Masaki, Morimoto, Kenji, Yamada, Tadaaki, Shiotsu, Shinsuke, Chihara, Yusuke, Yamada, Takahiro, Hiranuma, Osamu, Morimoto, Yoshie, Iwasaku, Masahiro, Tokuda, Shinsaku, Takeda, Takayuki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758423/
https://www.ncbi.nlm.nih.gov/pubmed/34791812
http://dx.doi.org/10.1111/1759-7714.14236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758423/
https://www.ncbi.nlm.nih.gov/pubmed/34791812
http://dx.doi.org/10.1111/1759-7714.14236

Ejemplares similares